2.61
-0.15 (-5.43%)
| Previous Close | 2.76 |
| Open | 2.83 |
| Volume | 6,824,007 |
| Avg. Volume (3M) | 3,829,764 |
| Market Cap | 588,698,560 |
| Price / Book | 2.82 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 - 11 Aug 2025 |
| Diluted EPS (TTM) | -1.16 |
| Total Debt/Equity (MRQ) | 40.68% |
| Current Ratio (MRQ) | 3.54 |
| Operating Cash Flow (TTM) | -223.15 M |
| Levered Free Cash Flow (TTM) | -168.60 M |
| Return on Assets (TTM) | -31.82% |
| Return on Equity (TTM) | -99.16% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Sana Biotechnology, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 2.0 |
| Average | 1.13 |
|
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 among others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 8.59% |
| % Held by Institutions | 93.73% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Flagship Pioneering Inc. | 31 Mar 2025 | 25,001,856 |
| Crestline Management, Lp | 31 Mar 2025 | 2,790,937 |
| Integral Health Asset Management, Llc | 31 Mar 2025 | 2,000,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 11.00 (HC Wainwright & Co., 321.46%) | Buy |
| Median | 8.00 (206.51%) | |
| Low | 5.00 (JMP Securities, 91.57%) | Buy |
| Average | 8.00 (206.51%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 2.19 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JMP Securities | 24 Jun 2025 | 5.00 (91.57%) | Buy | 2.61 |
| HC Wainwright & Co. | 24 Apr 2025 | 11.00 (321.46%) | Buy | 1.77 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 23 Jun 2025 | Announcement | Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression |
| 09 Jun 2025 | Announcement | Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions |
| 28 May 2025 | Announcement | Sana Biotechnology to Present at June 2025 Investor Conferences |
| 12 May 2025 | Announcement | Sana Biotechnology to Present at the BofA Securities 2025 Healthcare Conference |
| 08 May 2025 | Announcement | Sana Biotechnology Reports First Quarter 2025 Financial Results and Business Updates |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |